Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 3/20 | 0.42 |
| ▸ | FAAH | O00519 | 3/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 5/20 | 0.34 |
| ▸ | MGLL | Q99685 | 2/20 | 0.33 |
| ▸ | PPM1B | O75688 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | ITGB2 | P05107 | 2/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.32 |
| ▸ | ITGAL | P20701 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5114359 | 1.00 | MME (0.45) | MMEACEFAAHSMN1; SMN2BACE1 | |
| SCHEMBL5107129 | 0.86 | BACE1 (0.35) | MMEACEFAAHBACE1MGLL | |
| SCHEMBL5108957 | 0.86 | BACE1 (0.35) | MMEACEFAAHBACE1MGLL | |
| SCHEMBL5107124 | 0.86 | BACE1 (0.35) | MMEACEFAAHBACE1MGLL | |
| SCHEMBL5107132 | 0.86 | BACE1 (0.35) | MMEACEFAAHBACE1MGLL | |
| SCHEMBL5106156 | 0.82 | ACE (0.46) | ACEFAAHBACE1SLC6A2SLC6A3 | |
| SCHEMBL5106158 | 0.82 | ACE (0.46) | ACEFAAHBACE1SLC6A2SLC6A3 | |
| SCHEMBL4797908 | 0.79 | ACE (0.55) | MMEACEBACE1PPM1B | |
| SCHEMBL4797895 | 0.79 | ACE (0.55) | MMEACEBACE1PPM1B | |
| SCHEMBL8265802 | 0.79 | ACE (0.55) | MMEACEBACE1PPM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338974-B2 | Macrocyclic diaminopropanes as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | BRISTOL-MYERS SQUIBB COMPANY | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037868-A1 | 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome | APP, BACE1, PSEN1 | MME 340/4885ACE 28/4885FAAH 2534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.